Loading…
← CockpitCompetitor Analysis › 600079.SS Humanwell Healthcare (Group) Co.,Ltd. Class AOpen in the cockpit ↗

Humanwell Healthcare (Group) Co.,Ltd. Class A600079.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese pharmaceutical group with a leading position in anesthetic and pain-management drugs, plus broader generics and healthcare businesses.

Momentum leader 96
Mkt cap
$4.87B
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$32.2M
20-day average traded
Fwd P/E
13.8×
forward earnings
ROIC−WACC
+6.3 pp
WACC 5.0%
Hurdle
-12 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥20.12
1D-1.0%
1W+3.0%
1M+2.9%
3M+11.3%
6M+10.6%
YTD+11.1%
1Y-2.9%
ATR %2.0%
52w lowhigh4.0% off high

What Humanwell Healthcare (Group) does

Chinese pharmaceutical group with a leading position in anesthetic and pain-management drugs, plus broader generics and healthcare businesses.

Sells prescription drugs to hospitals, where its anaesthetics and pain relievers hold a strong position because they are tightly controlled substances that few makers are licensed to produce. Hospital pricing is shaped by China's government-led bulk-purchase tenders, which cut prices in exchange for volume. It also owns a US generic-drug business.

Products and services

  • Anesthetic/pain-management drugs
  • Generic pharmaceuticals
  • Reproductive health products

Customers

  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Anesthetics/pain drugs + generics

What could go right

  • Surgical volume growth driving anesthetic demand

What could go wrong

  • Centralized procurement (VBP) price cuts

Moat: narrow (regulatory licence, brand). Controlled-substance manufacturing licences for anesthetics are hard to obtain, protecting incumbents.

Headquarters: Wuhan, China · Employees: 17,153

Named competitors

Humanwell Healthcare (Group) at a glance

Size Humanwell Healthcare (Group) (600079.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.87B, the 481st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥20.12 on 18 Nov 2026.

Performance Over six months the shares gained 10.6%, against +10.5% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 1.5% over the last twelve months (peer median +13.1%); the operating margin is 15.1% (peer median 20.6%).

Valuation It trades at 13.8× forward earnings against a peer median of 28.7× (5th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 112600079.SS 112
Six months, rebased to 100: Humanwell Healthcare (Group) against the median of its 20 peers (local-currency closes).

Humanwell Healthcare (Group) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥24.5BCN¥23.8BCN¥25.3BCN¥24.4BCN¥22.2B
Revenue growth—-6%+4%+10%—
Gross profitCN¥12.5BCN¥10.9BCN¥10.6BCN¥10.7BCN¥9.21B
EBITDAn/aCN¥4.60BCN¥3.91BCN¥4.10BCN¥3.57B
Net incomeCN¥2.58BCN¥1.86BCN¥1.33BCN¥2.13BCN¥2.48B
Free cash flowCN¥2.11BCN¥1.83BCN¥1.17BCN¥89.4M-CN¥621M
Capital expenditureCN¥545MCN¥733MCN¥1.02BCN¥1.96BCN¥3.11B
Total debtCN¥8.15BCN¥8.99BCN¥9.52BCN¥9.95BCN¥11.0B

Quarterly statements and history in the cockpit →

Humanwell Healthcare (Group) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%ERASTVTX600085GLAXOEMCUREIPCALABPTCT326030LQDAIONSMANE0874688578AJANTPHARM600566CAMX002294603087GLAND600079.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Humanwell Healthcare (Group) is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×TVTX600085GLAXOEMCUREIPCALAB326030LQDA08746885784506CAMX002294603087GLAND600079.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Humanwell Healthcare (Group) is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%TVTX600085GLAXO326030LQDA688578600079.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Humanwell Healthcare (Group) is the large dot.

Humanwell Healthcare (Group) competitors and peer comparison

Head to head with its named competitors (600079.SS vs 002262.SZ vs 600276.SS vs 002653.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Humanwell Healthcare (Group) 600079.SS$4.87B+11%+2%15%13.8×-8.8%
Jiangsu Nhwa Pharmaceutical 002262.SZ$3.48B+8%+3%19%19.6×-2.1%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
Haisco Pharmaceutical 002653.SZ$9.13B+2%+42%18%36.0×19.0%

How Humanwell Healthcare (Group) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Humanwell Healthcare (Group) against its 20 peers (data as of 18 Nov 2026)
Measure600079.SSPeer medianRank in peer set
1-month return+2.9%-1.3%8th highest of 21
6-month return+10.6%+10.5%11th highest of 21
Distance from 52-week high-4.0%-30.1%4th highest of 21
Revenue growth (TTM)+1.5%+13.1%5th lowest of 19
Operating margin15.1%20.6%7th lowest of 19
Forward P/E13.8×28.7×5th cheapest of 18
Growth the price implies (Req g, 7 yrs)-8.8%7.3%2nd least demanding of 17
Growth delivered (Del g)+3.0%+13.0%3rd lowest of 17
Hurdle (Req g minus delivered)-11.8 pp-2.6 pp6th least demanding of 17
ROIC minus cost of capital+6.3 pp+3.4 pp7th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%

Questions

Who are Humanwell Healthcare (Group)'s main competitors?
Named competitors: Jiangsu Nhwa Pharmaceutical (002262.SZ), Jiangsu Hengrui Pharmaceuticals (600276.SS), Haisco Pharmaceutical (002653.SZ). The cockpit's measured peer set (industry) also includes Erasca (ERAS), Travere Therapeutics (TVTX), Beijing TongRenTang (600085.SS), GlaxoSmithKline Pharmaceuticals (GLAXO.NS), Emcure Pharmaceuticals (EMCURE.NS), IPCA Laboratories (IPCALAB.NS).
Is Humanwell Healthcare (Group) expensive compared with its peers?
On forward p/e it trades at 13.8× against a peer median of 28.7×, 5th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Humanwell Healthcare (Group) stock performed?
Over six months to 18 Nov 2026 the shares returned +10.6% against +10.5% for the median peer; over one year -2.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.